eagle-i University of Hawaii at ManoaUniversity of Hawaii at Manoa
See it in Search
This page is a preview of the following resource. Continue onto eagle-i search using the button on the right to see the full record.

Phase II study of sorafenib/bevacizumab as salvage therapy in patients with metastatic colorectal cancer

eagle-i ID


Resource Type

  1. Clinical trial


  1. ClinicalTrials.gov url
  2. Intervention
  3. Additional Topic(s)
    Combination antineoplastic chemotherapy
  4. Resource Description
    Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Sorafenib and bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving sorafenib together with bevacizumab may kill more tumor cells. This phase II trial is studying how well giving sorafenib together with bevacizumab works in treating patients with metastatic colorectal cancer.
  5. Contact
    Berenberg, Jeffrey
  6. PI
    Berenberg, Jeffrey
  7. Topic
    colorectal cancer
  8. Study Population
    Men and women 18 years and older with stage IV colorectal cancer
  9. Funded by
    North Central Cancer Treatment Group
  10. Phase
    Phase 2 clinical trial
  11. Performed by
    Clinical Protocol & Data Management Shared Resource
Provenance Metadata About This Resource Record
Copyright © 2016 by the President and Fellows of Harvard College
The eagle-i Consortium is supported by NIH Grant #5U24RR029825-02 / Copyright 2016